Phase I and pharmacokinetic study of E7070, a novel chloroindolyl-sulphonamide inhibiting the activation of cdk2 and cyclin E, administered as a 1-hour infusion every 3 weeks in patients with advanced cancer

E. Raymond; W.W. ten Bokkel Huinink; J. Taïeb; J.H. Beijnen; S.H. Faivre; J. Wanders; M. Ravic; P. Fumoleau; J.P. Armand; J.H.M. Schellens

Phase I and pharmacokinetic study of E7070, a novel chloroindolyl-sulphonamide inhibiting the activation of cdk2 and cyclin E, administered as a 1-hour infusion every 3 weeks in patients with advanced cancer

E. Raymond, W.W. ten Bokkel Huinink, J. Taïeb, J.H. Beijnen, S.H. Faivre, J. Wanders, M. Ravic, P. Fumoleau, J.P. Armand, J.H.M. Schellens

extern

Research output: Contribution to journal › Article › Academic › peer-review

Original language	Undefined/Unknown
Pages (from-to)	3508-3521
Number of pages	13
Journal	Journal of Clinical Oncology
Volume	20
Publication status	Published - 2002

Cite this

Raymond, E., ten Bokkel Huinink, W. W., Taïeb, J., Beijnen, J. H., Faivre, S. H., Wanders, J., Ravic, M., Fumoleau, P., Armand, J. P., & Schellens, J. H. M. (2002). Phase I and pharmacokinetic study of E7070, a novel chloroindolyl-sulphonamide inhibiting the activation of cdk2 and cyclin E, administered as a 1-hour infusion every 3 weeks in patients with advanced cancer. Journal of Clinical Oncology, 20, 3508-3521.

@article{941a1842a16343c48d2213b5fe0cc03d,

title = "Phase I and pharmacokinetic study of E7070, a novel chloroindolyl-sulphonamide inhibiting the activation of cdk2 and cyclin E, administered as a 1-hour infusion every 3 weeks in patients with advanced cancer",

author = "E. Raymond and {ten Bokkel Huinink}, W.W. and J. Ta{\"i}eb and J.H. Beijnen and S.H. Faivre and J. Wanders and M. Ravic and P. Fumoleau and J.P. Armand and J.H.M. Schellens",

year = "2002",

language = "Undefined/Unknown",

volume = "20",

pages = "3508--3521",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "American Society of Clinical Oncology",

}

Raymond, E, ten Bokkel Huinink, WW, Taïeb, J, Beijnen, JH, Faivre, SH, Wanders, J, Ravic, M, Fumoleau, P, Armand, JP & Schellens, JHM 2002, 'Phase I and pharmacokinetic study of E7070, a novel chloroindolyl-sulphonamide inhibiting the activation of cdk2 and cyclin E, administered as a 1-hour infusion every 3 weeks in patients with advanced cancer', Journal of Clinical Oncology, vol. 20, pp. 3508-3521.

Phase I and pharmacokinetic study of E7070, a novel chloroindolyl-sulphonamide inhibiting the activation of cdk2 and cyclin E, administered as a 1-hour infusion every 3 weeks in patients with advanced cancer. / Raymond, E.; ten Bokkel Huinink, W.W.; Taïeb, J. et al.
In: Journal of Clinical Oncology, Vol. 20, 2002, p. 3508-3521.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Phase I and pharmacokinetic study of E7070, a novel chloroindolyl-sulphonamide inhibiting the activation of cdk2 and cyclin E, administered as a 1-hour infusion every 3 weeks in patients with advanced cancer

AU - Raymond, E.

AU - ten Bokkel Huinink, W.W.

AU - Taïeb, J.

AU - Beijnen, J.H.

AU - Faivre, S.H.

AU - Wanders, J.

AU - Ravic, M.

AU - Fumoleau, P.

AU - Armand, J.P.

AU - Schellens, J.H.M.

PY - 2002

Y1 - 2002

M3 - Article

SN - 0732-183X

VL - 20

SP - 3508

EP - 3521

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

ER -